Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Boehringer Ingelheim
AstraZeneca
Teva
Novartis
Accenture
McKesson
Baxter
Medtronic
Queensland Health

Generated: January 21, 2018

DrugPatentWatch Database Preview

Canagliflozin; metformin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for canagliflozin; metformin hydrochloride and what is the scope of canagliflozin; metformin hydrochloride patent protection?

Canagliflozin; metformin hydrochloride
is the generic ingredient in two branded drugs marketed by Janssen Pharms and is included in two NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Canagliflozin; metformin hydrochloride has two hundred and eighteen patent family members in forty-four countries.

There are twenty drug master file entries for canagliflozin; metformin hydrochloride. One supplier is listed for this compound.
Summary for canagliflozin; metformin hydrochloride
International Patents:218
US Patents:6
Tradenames:2
Applicants:1
NDAs:2
Drug Master File Entries: 20
Suppliers / Packagers: 1
Clinical Trials: 1,882
Drug Prices:see low prices
DailyMed Link:canagliflozin; metformin hydrochloride at DailyMed
Pharmacology for canagliflozin; metformin hydrochloride

US Patents and Regulatory Information for canagliflozin; metformin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-003 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-003 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-004 Aug 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-004 Aug 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for canagliflozin; metformin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,482,330 Substituted fused heterocyclic C-glycosides ➤ Subscribe
7,816,330 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides ➤ Subscribe
7,084,124 Substituted indazole-O-glucosides ➤ Subscribe
7,511,022 Substituted indole-O-glucosides ➤ Subscribe
8,202,984 Glucopyranoside compound ➤ Subscribe
7,935,674 Indole derivatives ➤ Subscribe
7,816,331 Substituted indazole-O-glucosides ➤ Subscribe
7,820,630 Substituted indole-O-glucosides ➤ Subscribe
7,094,763 Substituted fused heterocyclic C-glycosides ➤ Subscribe
7,511,020 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for canagliflozin; metformin hydrochloride

Supplementary Protection Certificates for canagliflozin; metformin hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000050 Germany ➤ Subscribe PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1 /13/884/001-008 20131115
4 1-2014 Slovakia ➤ Subscribe PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
14/029 Ireland ➤ Subscribe PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
C0034 France ➤ Subscribe PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131115
00670 Netherlands ➤ Subscribe PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
2014008,C1651658 Lithuania ➤ Subscribe PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
2014008 Lithuania ➤ Subscribe PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
0140011 00102 Estonia ➤ Subscribe PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
2014 00024 Denmark ➤ Subscribe PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
0670 Netherlands ➤ Subscribe PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Army
Federal Trade Commission
Daiichi Sankyo
Fuji
Johnson and Johnson
Cantor Fitzgerald
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot